ClinConnect ClinConnect Logo
Search / Trial NCT06686017

Virtuos Bone Graft in Lumbar Fusion

Launched by ORTHOFIX INC. · Nov 11, 2024

Trial Information

Current as of June 27, 2025

Enrolling by invitation

Keywords

Lumbar Spinal Fusion Cellular Based Allograft Anterior Lumbar Interbody Fusion (Alif) Lateral Lumbar Interbody Fusion (Llif)

ClinConnect Summary

Single arm prospectively enrolled observational study of subjects who undergo lumbar spinal fusion at one or two levels with an anterior or lateral surgical approach using a cellular based allograft (Virtuos) as the bone graft There is no experimental intervention for this study. Subjects will be treated per standard of care by their attending physician/surgeon. The primary endpoint in this study is fusion success at 12 months. as determined by the attending physician/surgeon using CT as the imaging modality. The fusion rates observed at 12-months will be compared to an historical group of ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subject must be 18 years of age (≥ 18 years) or older at the time of consent.
  • Subject must undergo lumbar interbody fusion study at 1-2 contiguous levels.
  • Virtuos must be the primary bone graft (≥ 50% of the total graft volume) and may be augmented with autograft or cortical or cancellous bone chips.
  • Subject must be willing and able to sign an informed consent document.
  • Subject must be willing and able to return for all follow-up visits, agree to participate in postoperative clinical and radiographic evaluations, and comply with the required study protocol.-
  • Exclusion Criteria:
  • Subject is under 18 years of age (\<18) at the time of consent.
  • Subject has had prior lumbar spine fusion surgery at any level.
  • Subject has greater than grade 1 spondylolisthesis of the lumbar spine. Subject is currently undergoing treatment for malignancy or has undergone treatment for malignancy in the past 5 years (benign skin cancer is permitted)
  • Subject has an active local or systemic infection or is undergoing adjunctive treatment for local or systemic infection

About Orthofix Inc.

Orthofix Inc. is a global medical device company specializing in innovative solutions for spine and orthopedic conditions. With a commitment to advancing patient care through cutting-edge technology and research, Orthofix develops a range of products, including biologics, bone growth stimulators, and fixation devices. The company is dedicated to conducting clinical trials that enhance the understanding and effectiveness of its products, ensuring safety and efficacy for patients while driving advancements in the field of orthopedic and spine surgery. With a focus on collaboration and integrity, Orthofix aims to improve outcomes for healthcare providers and their patients worldwide.

Locations

Myrtle Beach, South Carolina, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported